Seizure Cycle Tracking May Flag Medication Changes, Pilot Shows

Seizure diaries kept by people with epilepsy contain enough signal to detect changes in multiday seizure cycles after antiseizure medication adjustments, according to a retrospective pilot study published online 27 September 2026 in Seizure: European Journal of Epilepsy.

The study, led by Ashley Reynolds with co-authors Rachel E. Stirling, Samuel Håkansson, Michaela Vranic-Peters, Philippa Karoly, Alan Lai, Ewan S. Nurse, David B. Grayden, Mark J. Cook, and Andre Peterson, set out to test a practical question: can clinicians tell, from diary data alone, whether a medication change has disrupted a patient's characteristic seizure rhythm?

The work is a feasibility pilot, not a controlled trial. The authors designed it as a first step toward using patient-maintained seizure diaries — a fixture of everyday epilepsy care — as a quantitative marker of treatment response. The retrospective design means the analysis looks backward at existing diary records rather than prospectively recruiting patients for continuous monitoring.

For the reading room and the epilepsy monitoring context, the study's relevance is straightforward. Seizure diaries are already standard clinical practice, but they are typically reviewed impressionistically. This study asks whether the same low-cost data stream can support formal cycle analysis of the kind more often associated with implanted neurophysiology — the chronic intracranial EEG work pioneered by several of the same authors' group, including Cook, Grayden, Karoly, and Peterson, in long-term device studies.

The question of multiday seizure periodicity matters clinically. Prior research, including work from this Melbourne-centered collaboration, has shown that many patients have robust circaseizure rhythms — cycles ranging from roughly daily to weekly to monthly — that shape when seizures occur. If an antiseizure medication change alters those cycles, diary-based cycle tracking could offer an early, non-invasive read on whether a new regimen is working, before months of seizure counts accumulate.

The authors frame the study explicitly as a feasibility pilot. That label carries weight for readers evaluating the evidence: the cohort is small by design, the analysis is retrospective, and the results should be read as a proof of concept for the method rather than as evidence that diary-based cycle monitoring improves outcomes. The study does not test an FDA-cleared or commercial device; it evaluates an analytical approach applied to routinely collected clinical data.

What the pilot demonstrates is that the diary-based signal is detectable — that changes in seizure cycles following medication adjustments can be identified from patient records. The recording method here is not scalp EEG, intracranial EEG, ECoG, or MEG, but patient-reported diary entries, and the claims should be understood accordingly: this is analysis of self-reported seizure timing, with all the adherence and recall limitations that entails.

The clinical logic is nonetheless grounded. Medication changes are among the most common decision points in epilepsy management, and clinicians currently lack fast feedback on whether a regimen change is shifting a patient's seizure dynamics. Cycle-based analysis of diary data could complement seizure-frequency counting, potentially flagging responsiveness — or its absence — on a shorter timescale.

The next steps the pilot sets up are prospective validation in larger cohorts, comparison against objective neurophysiological recordings, and testing of whether cycle-guided medication titration changes clinical decisions. Whether diary-based cycle tracking can move from feasibility demonstration to a practical tool in the monitoring unit and outpatient clinic will depend on those studies.